Close Menu
TIMES24H – International Breaking News
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    TIMES24H – International Breaking News
    • Hot!
      • Vietnam
      • Asia
      • Video
    • World
      • PR Newswire
      • Media OutReach Newswire
      • GLOBENEWSWIRE
    • Business
    • Life
      • Lifestyle
      • Recipes
      • Fashion
    • Sport
    • Tech
      • Gadgets
    Media Outreach Newswire
    TIMES24H – International Breaking News
    Home»Lifestyle»Media OutReach Newswire»Mayo Clinic Laboratories Invests in Pathology Asia Holdings and LifeStrands Genomics to Advance Diagnostics and Precision Medicine
    Media OutReach Newswire

    Mayo Clinic Laboratories Invests in Pathology Asia Holdings and LifeStrands Genomics to Advance Diagnostics and Precision Medicine

    Media OutReach NewswireBy Media OutReach NewswireSeptember 23, 2026Updated:September 23, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    ROCHESTER, MINN., US / SINGAPORE – Media OutReach Newswire – 23 September 2026 – Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand.

    Mayo Clinic Laboratories and PAH are deepening a long-term relationship that brings together Mayo’s global clinical and diagnostic expertise with the regional healthcare network, capabilities and market knowledge of PAH and its genomics subsidiary, LifeStrands Genomics. William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, has been appointed Scientific Adviser to PAH.

    Genomics is a central focus of the collaboration, delivered through LifeStrands Genomics. Mayo Clinic Laboratories and LifeStrands Genomics will work together to broaden access to advanced molecular and genomic testing across Southeast Asia, Australia and New Zealand, with applications spanning the identification of genetic conditions, disease risk assessment, diagnosis, and treatment planning, enabling healthcare providers to integrate clinically relevant genomic insights into more personalised patient care.

    LifeStrands Genomics will operate as “LifeStrands in collaboration with Mayo Clinic Laboratories” in certain markets, reflecting the organisations’ shared commitment to expanding access to advanced genomic testing and precision medicine across the region.

    Together, the organisations will pursue joint scientific initiatives, education and thought leadership to support the integration of genomics into patient care. “Healthcare providers across Southeast Asia, Australia and New Zealand are increasingly seeking advanced diagnostic solutions to guide patient care,” said Dr. Morice. “Our collaboration with PAH and LifeStrands Genomics reflects our commitment to a long-term strategic relationship that unites complementary strengths in laboratory diagnostics and genomics. Through this collaboration, we are bringing advanced diagnostic capabilities closer to patients and equipping healthcare providers with the insights needed to deliver personalised care.”

    “Mayo Clinic Laboratories’ investment marks an important milestone in our relationship and a strong foundation for the next phase of diagnostic innovation across the region,” Christopher Ting, M.D., founder and CEO of Pathology Asia Holdings, added. “Combining Mayo Clinic Laboratories’ global clinical and scientific expertise with PAH’s regional diagnostic capabilities and network will enable us to broaden access to advanced testing and increase access to genomics and precision medicine capabilities across Southeast Asia, Australia and New Zealand.”

    Hashtag: #MayoClinicLaboratories #PathologyAsia #LifeStrands #LifeStrandsGenomics #LifeStrandsGenomicsAustralia #DNALAB #DNALaboratories #PrecisionMedicine

    https://www.lifestrandsgx.com/
    https://www.linkedin.com/company/lifestrandsgx/

    The issuer is solely responsible for the content of this announcement.

    Mayo Clinic Laboratories

    Mayo Clinic Laboratories, the global leader in turning test results into clinical answers, provides advanced testing and pathology services for healthcare organisations worldwide in partnership with Mayo Clinic’s Department of Laboratory Medicine and Pathology. Mayo Clinic Laboratories offers more than 4,400 tests and pathology services, delivering specialised diagnostic expertise to help healthcare providers make informed decisions and improve patient care.

    Pathology Asia

    Pathology Asia is a leading regional provider of pathology and laboratory diagnostics services, with operations across Singapore, Malaysia, Indonesia, Thailand, Vietnam, the Philippines and Australia. Its network encompasses established diagnostics brands including Innoquest, Singapore Diagnostics, TissuPath and Safework Health, as well as its specialist genomics businesses, LifeStrands Genomics and DNA Laboratories. Pathology Asia delivers a comprehensive range of pathology, molecular and genomic testing services to healthcare providers, hospitals and patients across the region through its network of internationally accredited laboratories.

    LifeStrands Genomics

    LifeStrands Genomics is a leading Asia-Pacific clinical genomics company comprising three specialist laboratories: LifeStrands Genomics Singapore, LifeStrands Genomics Australia, and DNA Laboratories. Together, the group provides advanced molecular and genomic testing across oncology, reproductive health, inherited disorders and wellness. Operating through CAP- and ISO 15189-accredited laboratories, LifeStrands Genomics delivers clinically actionable insights that empower healthcare professionals to make informed decisions, advance personalised care and improve patient outcomes.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Drive to Great: BAIC FOTON Africa Partners Conference Set to Open

    October 27, 2026

    HKSTP Showcases 24 Greentech Companies at Eco Expo Asia 2026

    October 27, 2026

    Huitongda Network (9878.HK) Subsidiary Jujia Yuntong Launches iPhone Duo Across Over 1,000 Apple Authorised Stores

    October 27, 2026
    Leave A Reply Cancel Reply

    Latest News
    Envision Energy Unveils AI-powered New Energy System for Mining and Smelting Industry at All Energy Australia

    Envision Energy Unveils AI-powered New Energy System for Mining and Smelting Industry at All Energy Australia

    October 28, 2026
    OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW

    OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW

    October 28, 2026
    ATMOCE Brings Flexible AC Stackable Storage and 15-Year M-ELV Battery Warranty to All Energy Australia 2026

    ATMOCE Brings Flexible AC Stackable Storage and 15-Year M-ELV Battery Warranty to All Energy Australia 2026

    October 27, 2026
    etisalat achieves record 9M 2026 performance as consolidated net profit rises 46% YoY to AED 17.2 billion

    etisalat achieves record 9M 2026 performance as consolidated net profit rises 46% YoY to AED 17.2 billion

    October 27, 2026
    DMCA.com Protection Status
    Facebook X (Twitter) Instagram Pinterest
    TIMES24H
    Global News · Trusted Information · Clear Perspectives
    TIMES24H is a global news platform delivering timely, reliable, and insightful coverage across technology, business, lifestyle, and current affairs. Our mission is to provide readers with clear perspectives and trusted information to navigate a fast-changing world.
    News & Editorial: news@times24h.com
    © 2026 TIMES24H . All rights reserved.

    Type above and press Enter to search. Press Esc to cancel.